Department of Metabolic Diseases, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
Laboratory Genetic Metabolic Diseases, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam Gastroenterology and Metabolism, Amsterdam, The Netherlands.
J Inherit Metab Dis. 2020 Sep;43(5):969-980. doi: 10.1002/jimd.12266. Epub 2020 Jun 5.
Cardiomyopathy can be a severe complication in patients with long-chain fatty acid β-oxidation disorders (LCFAOD), particularly during episodes of metabolic derangement. It is unknown whether latent cardiac abnormalities exist in adult patients. To investigate cardiac involvement in LCFAOD, we used proton magnetic resonance imaging (MRI) and spectroscopy ( H-MRS) to quantify heart function, myocardial tissue characteristics, and myocardial lipid content in 14 adult patients (two with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD); four with carnitine palmitoyltransferase II deficiency (CPT2D); and eight with very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)) and 14 gender-, age-, and BMI-matched control subjects. Examinations included cine MRI, MR tagging, native myocardial T and T mapping, and localized H-MRS at 3 Tesla. Left ventricular (LV) myocardial mass (P = .011) and the LV myocardial mass-to-volume ratio (P = .008) were higher in patients, while ejection fraction (EF) was normal (P = .397). LV torsion was higher in patients (P = .026), whereas circumferential shortening was similar compared with controls (P = .875). LV hypertrophy was accompanied by high myocardial T values (indicative of diffuse fibrosis) in two patients, and additionally a low EF in one case. Myocardial lipid content was similar in patients and controls. We identified subclinical morphological and functional differences between the hearts of LCFAOD patients and matched control subjects using state-of-the-art MR methods. Our results suggest a chronic cardiac disease phenotype and hypertrophic LV remodeling of the heart in LCFAOD, potentially triggered by a mild, but chronic, energy deficiency, rather than by lipotoxic effects of accumulating lipid metabolites.
心肌病可能是长链脂肪酸β氧化障碍(LCFAOD)患者的严重并发症,尤其是在代谢紊乱发作期间。目前尚不清楚成年患者是否存在潜在的心脏异常。为了研究 LCFAOD 中的心脏受累情况,我们使用质子磁共振成像(MRI)和波谱(H-MRS)来定量心脏功能、心肌组织特征和心肌脂质含量,研究对象为 14 名成年患者(2 名长链 3-羟基酰基辅酶 A 脱氢酶缺乏症(LCHADD)患者;4 名肉碱棕榈酰基转移酶 II 缺乏症(CPT2D)患者;8 名极长链酰基辅酶 A 脱氢酶缺乏症(VLCADD)患者)和 14 名性别、年龄和 BMI 匹配的对照组。检查包括电影 MRI、MR 标记、心肌 T1 和 T2 映射以及 3T 局部 H-MRS。左心室(LV)心肌质量(P =.011)和 LV 心肌质量与体积比(P =.008)在患者中更高,而射血分数(EF)正常(P =.397)。LV 扭转在患者中更高(P =.026),而圆周缩短与对照组相似(P =.875)。LV 肥大伴有两名患者心肌 T 值升高(提示弥漫性纤维化),此外一名患者 EF 降低。患者和对照组的心肌脂质含量相似。我们使用最先进的 MR 方法发现 LCFAOD 患者和匹配对照组的心脏存在亚临床形态和功能差异。我们的结果表明 LCFAOD 中的心脏存在慢性心脏疾病表型和 LV 肥厚重塑,这可能是由轻微但慢性的能量缺乏引起的,而不是由累积脂质代谢物的脂毒性作用引起的。